1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGRQ
Eiger BioPharmaceuticals, Inc.US flagOther OTC
8.50
USD
+0.50
- -
12.59MMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
10.73
9.72
10.68
10.69
Basic EPS, GAAP
-367.01
-600.49
-530.86
-648.51
-1,865.83
-235.16
-145.9
-114.63
-92.5
-69.34
-29.98
-69.74
-50.78
-50.82
Free Cash Flow per Basic Share
-294.71
-549.07
-414.56
-574.66
-1,285.57
-189.92
-132.05
-93.68
-84.38
-67.63
-106.12
-60.07
-50.66
-50.7
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-3,461.99
-2,866.39
-2,805.25
-26,729.69
-381.3
-408.33
-374.54
-317.87
-326.68
-300.83
-315.06
-346.93
-347.19
Tangible Book Value per Share
- -
-1,062.48
-1,298.21
1,381.28
4,419.19
203.37
77.41
145.7
74.36
101.3
63.99
39.86
-9.79
-9.8
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12
13
16
16
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-633.66
-687.78
-455.12
-455.12
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
Net Income, GAAP
-7
-16
-20
-34
-13
-47
-42
-52
-70
-65
-34
-97
-75
-75
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-279.34
-717.71
-475.26
-475.26
Working Capital
- -
31
12
81
32
55
35
92
83
121
73
92
-15
-15
LT Debt
- -
- -
- -
10
- -
15
13
26
32
32
24
40
- -
- -
Total Equity
- -
24
9
72
32
41
23
67
56
95
72
55
-14
-14
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'23
ST Debt
- -
- -
41
LT Borrowings
40
41
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
31
13
10

Working Capital

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'23
Total Current Assets
70
55
38
Cash, Cash Equivalents & STI
54
39
25
Accounts Receivable, Net
4
1
2
Inventories
1
1
2
Total Current Liabilities
17
17
53
Payables & Accruals
11
10
7
ST Debt
- -
- -
41
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
69.51%
-24.1%
-126.14%
Free Cash Flow
43.87%
19.42%
-10.28%
Net Income, GAAP
41.73%
28.32%
-22.54%
Sales/Revenue/Turnover
- -
- -
16.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
4
2
3
3
12
2022
3
4
4
3
13
2023
4
5
3
4
16

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
25.89
-16.95
-19.64
-19.2
-29.98
2022
-19.27
-15.25
-18.48
-17.11
-69.74
2023
-15.48
-14.02
-12.2
- -
-50.78

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
David Apelian
Full Time Employees
25
Sector
Healthcare
Industry
Biotechnology
Address
2155 Park Boulevard Palo Alto CA United States of America 94306
IPO Date
Jan 30, 2014
CIK
0001305253
Website
eigerbio.com
Similar Companies
Oncternal Therapeutics, Inc. (ONCT)
Faron Pharmaceuticals Oy (FARN.L)
PhaseRx, Inc. (PZRXQ)
MEDINET Co., Ltd. (2370.T)
NANO MRNA Co.,Ltd. (4571.T)
Noxopharm Limited (NOXOF)
Business
I did not find relevant recent major company changes or other updated details specifically about Eiger BioPharmaceuticals, Inc. from the initial broad search results. I will conduct a more focused search specifically on Eiger BioPharmaceuticals, Inc. including their latest news, partnerships, acquisitions, product launches, and strategic updates.

Company News

APIChatGPT

  • reuters.com

    Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar